Corrigendum: Oral Hypoxia-Inducible Factor 2α Inhibitor Belzutifan in Ocular von Hippel-Lindau Disease : Subgroup Analysis of the Single-Arm Phase 2 LITESPARK-004 Study (Ophthalmology (2024) 131(11) (1324–1332), (S0161642024003191), (10.1016/j.ophtha.2024.05.024))

The publisher would like to note a correction to the study sponsor disclosures of “Oral Hypoxia-Inducible Factor 2α Inhibitor Belzutifan in Ocular von Hippel-Lindau Disease” (Ophthalmology. 2024; 131: 1324-1332.) The study sponsor disclosure should read as follows (changes in bold): Study funding and medical writing support was provided by Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc., Rahway, NJ, USA. This project has also been supported by the intramural program at the National Institutes of Health (National Cancer Institute and National Eye Institute), and by federal funds from the National Eye Institute, National Institutes of Health, Department of Health and Human Services.